氟达拉滨与环磷酰胺联合清髓性全身照射作为急性髓系白血病患者异基因造血细胞移植预处理方案的比较:欧洲血液与骨髓移植学会急性白血病工作组研究
该回顾性匹配配对分析比较了氟达拉滨联合12 Gy全身照射(FluTBI12Gy)与环磷酰胺联合12 Gy全身照射(CyTBI12Gy)在完全缓解期接受异基因造血细胞移植的急性髓系白血病成人患者中的结局。每组109例患者,2年复发率、非复发死亡率、无白血病生存率和总生存率均无显著差异,但FluTBI12Gy组2-4级急性移植物抗宿主病累积发生率显著更低(16% vs 34%,p=.005)。作者结论认为在12 Gy全身照射方案中,环磷酰胺可被氟达拉滨替代而不影响疗效。
要点
- 在12 Gy全身照射方案中,氟达拉滨替代环磷酰胺不影响2年复发率、非复发死亡率、无白血病生存率和总生存率。
- FluTBI12Gy组2-4级急性移植物抗宿主病累积发生率显著低于CyTBI12Gy组(16% vs 34%,p=.005)。
- 3-4级急性移植物抗宿主病和慢性移植物抗宿主病发生率两组无显著差异。
核心结论
- 对于完全缓解期接受异基因造血细胞移植的急性髓系白血病患者,在基于12 Gy全身照射的方案中,环磷酰胺可被氟达拉滨替代而不影响疗效。
- FluTBI12Gy与2-4级急性移植物抗宿主病风险降低相关,并具有令人鼓舞的生存率。
研究设计与样本
- 该研究为回顾性比较分析,比较CyTBI12Gy与FluTBI12Gy在完全缓解期接受异基因造血细胞移植的急性髓系白血病患者中的结局,供者来源为匹配同胞或无关供者。
- 符合纳入标准的成人患者共1684例,经匹配配对分析每组纳入109例患者。
主要发现
- 2年复发累积发生率FluTBI12Gy组为25%,CyTBI12Gy组为28%(p=.44)。
- 非复发死亡率FluTBI12Gy组为17%,CyTBI12Gy组为19%(p=.89)。
- 无白血病生存率FluTBI12Gy组为65%,CyTBI12Gy组为54%(p=.28);总生存率FluTBI12Gy组为70%,CyTBI12Gy组为60.5%(p=.17)。
- 2-4级急性移植物抗宿主病累积发生率FluTBI12Gy组为16%,显著低于CyTBI12Gy组的34%(p=.005)。
- 3-4级急性移植物抗宿主病和慢性移植物抗宿主病发生率两组无显著差异;无移植物抗宿主病且无复发生存概率FluTBI12Gy组为49%,CyTBI12Gy组为41%(p=.17)。
临床怎么用
- 作者结论认为,对于完全缓解期接受异基因造血细胞移植的急性髓系白血病患者,在基于12 Gy全身照射的方案中,环磷酰胺可被氟达拉滨替代而不影响疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Total body irradiation (TBI) at a dose of 12 Gy combined with cyclophosphamide (CyTBI12Gy) is one of the standard myeloablative regimens for patients with acute myeloid leukemia (AML) treated with allogeneic hematopoietic cell transplantation (allo-HCT). In clinical practice, cyclophosphamide may be substituted with fludarabine (FluTBI12Gy) to reduce toxicity. We retrospectively compared outcomes of CyTBI12Gy with FluTBI12Gy for patients with AML treated in complete remission (CR) with allo-HCT from either a matched sibling or unrelated donor. Of 1684 adults who met inclusion criteria, 109 patients in each group were included in a matched-pair analysis. The cumulative incidence of relapse at 2 years was 25% in the FluTBI12Gy compared to 28% in the CyTBI12Gy group (p = .44) while non-relapse mortality (NRM) was 17% versus 19%, (p = .89) respectively. The rates of leukemia-free survival and overall survival were 65% versus 54% (p = .28) and 70% versus 60.5% (p = .17). Cumulative incidence of grade 2-4 acute graft-versus-host disease (GVHD) was significantly lower for FluTBI12Gy than CyTBI12Gy (16% vs. 34%, p = .005), while the incidences of grade 3-4 acute GVHD and chronic GVHD did not differ significantly. The probability of GVHD and relapse-free survival was 49% in the FluTBI12Gy and 41% in the CyTBI12Gy group (p = .17). We conclude that for patients with AML treated with allo-HCT in CR, cyclophosphamide may be substituted with fludarabine in a regimen based on TBI at a dose of 12 Gy without negative impact on the efficacy. FluTBI12Gy is associated with reduced risk of grade 2-4 acute GVHD and encouraging survival rates.
引用
- Giebel S, Labopin M, Schroeder T, et al. Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2023. PMID: 36626592. doi:10.1002/ajh.26825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。